株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国の開発業務受託機関 (CRO) 産業レポート

China Contract Research Organization (CRO) Industry Report, 2019-2025

発行 ResearchInChina 商品コード 304490
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
中国の開発業務受託機関 (CRO) 産業レポート China Contract Research Organization (CRO) Industry Report, 2019-2025
出版日: 2019年03月11日 ページ情報: 英文 150 Pages
概要

当レポートでは、中国の開発業務受託機関 (CRO) 産業について調査し、産業の現状、市場規模、競合情勢、市場特徴、動向、国際環境、産業環境、政策環境、今後の発展見通しの分析を提供しており、主要企業のプロファイルを交えて、お届けいたします。

第1章 医薬品アウトソーシングの概要

  • 定義
  • 分類
  • CRO (開発業務受託機関)

第2章 世界のCRO産業における進化

  • 発展の経緯
  • 発展の背景
  • 市場規模
  • 競合情勢

第3章 中国のCRO産業における進化

  • 発展環境
  • 現状
  • 市場規模
  • 競合パターン
  • 発展動向

第4章 主要中国企業

  • Wuxi AppTec
  • Hangzhou Tigermed Consulting Co., Ltd.
  • Guangzhou Boji Medical Biotechnological Co., Ltd.
  • Shanghai Medicilon Inc.
  • Porton Fine Chemical Ltd.
  • JOINN Laboratories, Inc.
  • Pharmaron
  • Obio Technology (Shanghai) Corp., Ltd.
  • Asymchem Laboratories Inc.
  • Shanghai ChemPartner Co., Ltd.

第5章 主要国外企業

  • LabCorp
  • QuintilesIMS
  • Parexel
  • Charles River
  • PPD
  • inVentiv Health
図表

Selected Charts

  • Classification of Pharmaceutical Outsourcing
  • R&D Process of New Drugs
  • Corresponding Relationship between New Drug R & D Process, New Drug R & D Discipline and CRO Services
  • New Drug R&D Cost Structure
  • Global Pharmaceutical Market Size, 2012-2018
  • Global Pharmaceutical Market Size, 2018-2025E
  • Global Pharmaceutical Market Size (by Type), 2012-2018
  • Global Pharmaceutical Market Size (by Type), 2012-2025E
  • Global Pharmaceutical Market Size (by Region), 2012-2018E
  • Global Pharmaceutical Market Size (by Region), 2018-2025E
  • TOP20 Pharmaceutical Companies by Revenue, 2017
  • New Drug Approvals of Global Pharmaceutical Companies (by Company Size), 2013-2022E
  • Global Pharmaceutical R & D Investment (by Company Size), 2013-2018
  • Global Pharmaceutical R & D Investment (by Company Size), 2018-2025E
  • Global Pharmaceutical R & D Investment (by Medicine Type), 2013-2018
  • Global Pharmaceutical R & D Investment (by Medicine Type), 2018-2025E
  • Average Costs of New Drugs from R&D to Approved Launch
  • Cumulative Success Rate of New Drug R&D from Phase I to III
  • Number of Drugs in R&D (by Phase), 2017 VS 2016
  • Scale and YoY Growth of Global CRO Industry, 2011-2018
  • Scale and YoY Growth of Global CRO Industry, 2018-2025E
  • Comparison between Global Major CRO Companies
  • Market Share of Major Global CRO Companies, 2018
  • M&A Cases of Global Major CRO Companies
  • Comparison of Major Global CRO Companies by Revenue, 2014-2018
  • Policies on China's CRO Industry, 2010-2018
  • China Pharmaceutical Market Size and % in Global Total, 2012-2018
  • China Pharmaceutical Market Size and % in Global Total, 2018-2025E
  • China Pharmaceutical Market Size (by Type), 2012-2018
  • China Pharmaceutical Market Size (by Type), 2018-2025E
  • China Pharmaceutical R & D Investment and % in Global Total, 2013-2018
  • China Pharmaceutical R & D Investment and % in Global Total, 2018-2025E
  • Development Course of CRO Industry in China
  • Comparison of Pharmaceutical R&D Costs in China and Developed Countries
  • Cases of Multinational Pharmaceutical Enterprises' R&D Centers in China, 2001-2018
  • Scale and YoY Growth of China's CRO Industry, 2011-2018
  • Scale and YoY Growth of China's CRO Industry, 2018-2025E
  • Layout of Major Global CRO Companies in Asia
  • Comparison of Major Chinese CRO Companies
  • Market Share of Major Chinese CRO Companies, 2017
  • Market Share of Major Chinese CRO Companies, 2018
  • Comparison of Major Chinese CRO Companies by Revenue, 2014-2018
  • Comparison of Major Chinese CRO Companies by Net Income, 2014-2018
  • Listing of Local Chinese CRO Companies
  • Layout of Chinese Companies in CRO, 2015-2017
  • M & A Cases of Chinese CRO Companies, 2016-2018
  • China's Policies on Consistency Assessment, 2012-2018
  • Major Business of Wuxi AppTec
  • Serivce Provided by Wuxi AppTec to Pharmaceutical Companies in New Medicine R&D Stage
  • Revenue and Net Income of Wuxi AppTec, 2014-2018
  • Revenue of Wuxi AppTec by Product, 2015-2018
  • Revenue of Wuxi AppTec by Region, 2014-2017
  • Revenue Structure of Wuxi AppTec by Region, 2014-2017
  • Gross Margin of Wuxi AppTec, 2015-2018
  • Gross Margin of Wuxi AppTec by Product, 2015-2018
  • Revenue from Top Ten Clients of Wuxi AppTec, 2015-2017
  • R&D Investment and % of Total Revenue of Wuxi AppTec, 2014-2018
  • IPO Raised Investment Projects of Wuxi AppTec
  • Revenue from CRO Business (by Sector) of Wuxi AppTec, 2014-2018
  • Gross Margin of CRO Business (by Sector) of Wuxi AppTec, 2014-2018
  • Revenue and Net Income of Tigermed, 2013-2018
  • Revenue of Tigermed by Business, 2014-2018
  • Revenue Structure of Tigermed by Business, 2014-2018
  • Revenue of Tigermed by Region, 2014-2018
  • Revenue Structure of Tigermed by Region, 2014-2018
  • Gross Margin of Tigermed by Business, 2014-2018
  • R&D Investment of Tigermed and % of Total Revenue, 2013-2018
  • Expansion Course of Tigermed, 2004-2017
  • Main Business of Boji Medical Biotechnological
  • Revenue and Net Income of Boji Medical Biotechnological, 2014-2018
  • Revenue of Boji Medical Biotechnological by Business, 2014-2018
  • Revenue Structure of Boji Medical Biotechnological, 2014-2018
  • Gross Margin of Boji Medical Biotechnological by Product, 2014-2018
  • R&D Investment of Boji Medical Biotechnological and % of Total Revenue, 2014-2018
  • IPO Project Progress of Boji Medical Biotechnological, as of H1 2018
  • Development Course of Meidicilon
  • Revenue and Net Income of of Meidicilon, 2014-2016
  • Revenue of Meidicilon by Business, 2014-2016
  • Revenue Structure of Meidicilon by Business, 2014-2016
  • Revenue of Meidicilon by Region, 2014-2016
  • Gross Margin of Meidicilon by Business, 2014-2016
  • R&D Investment of Meidicilon and % of Total Revenue, 2014-2016
  • IPO Fund-raised Projects of Meidicilon, 2017
  • Top Five Clients of Meidicilon and % in Total Revenue, 2014-2016
  • Revenue and Net Income of Porton, 2014-2018
  • Revenue of Porton by Business, 2014-2017
  • Revenue Structure of Porton by Business, 2014-2017
  • Revenue of Porton by Region, 2014-2018
  • Revenue Structure of Porton by Region, 2014-2018
  • Gross Margin of Porton by Business, 2014-2017
  • R&D Investment of Porton and % of Total Revenue, 2014-2017
  • Subscription of Porton in Establishment of the Industrial Fund, 2019
  • Revenue from Top 5 Clients of Porton and % in Total Revenue, 2015-2017
  • Revenue and Net Income of JOINN Laboratories, 2014-2018
  • Revenue of JOINN Laboratories (by Business), 2014-2018
  • Revenue Structure of JOINN Laboratories (by Business), 2014-2018
  • Gross Margin of JOINN Laboratories, 2014-2018
  • Business Advantages of JOINN Laboratories
  • R & D Expenditure of JOINN Laboratories and % of Total Revenue, 2014-2018
  • Investment Projects of JOINN Laboratories by Raising Funds via IPO, 2017
  • JOINN Laboratories' Revenue from Top 5 Clients and % of Total Revenue, 2014-2017
  • Pharmaron's Revenue and Net Income, 2014-2018
  • Pharmaron's Revenue (by Business), 2014-2018
  • Pharmaron's Revenue (by Region), 2015-2018
  • Pharmaron's Gross Margin, 2015-2018
  • Pharmaron's Gross Margin (by Business), 2015-2018
  • Composition of Pharmaron's R & D Division
  • Pharmaron's Staff Structure by Division, as of June 30, 2018
  • Pharmaron's M&A Cases, 2016-2017
  • Pharmaron's Revenue from Top 5 Clients and % of Total Revenue, 2014-2018
  • Revenue and Net Income of Obio Technology (Shanghai), 2014-2018
  • Revenue of Obio Technology (Shanghai) by Business, 2014-2018
  • Revenue Structure of Obio Technology (Shanghai) by Business, 2014-2018
  • Gross Margin of Obio Technology (Shanghai), 2014-2018
  • R&D Investment of Obio Technology (Shanghai) and % of Total Revenue, 2014-2018
  • Revenue from Top 5 Clients of Obio Technology (Shanghai) and % in Total Revenue, 2014-2017
  • Major Clients of Huawe Medicine
  • Progress of Innovation Projects of Huawe Medicine under R&D
  • Development Course of Shanghai ChemPartner
  • Equity Structure of Shanghai ChemPartner's Subsidiaries
  • Main Content of Shanghai ChemPartner's CRO Business
  • Main Content of Shanghai ChemPartner's CMO Business
  • Revenue of Shanghai ChemPartner (by Business), 2015-2018
  • Revenue Structure of Shanghai ChemPartner (by Business), 2015-2018
  • Shanghai ChemPartner's Revenue from Major Customers and % of Total Revenue, 2015-2017
  • LabCorp's Revenue and Net Income, 2013-2018
  • LabCorp's Revenue (by Division), 2013-2018
  • LabCorp's Revenue Structure (by Division), 2013-2018
  • LabCorp's CRO Revenue and % of Total Revenue, 2013-2018
  • Revenue and Net Income of IQVIA, 2014-2018
  • Operating Revenue of IQVIA by Region and by Business, 2016-2018
  • Operating Revenue Structure of IQVIA by Region and by Business, 2016-2018
  • Business Scope of Parexel
  • Revenue and Net Income of Parexel, FY2014-FY2017
  • Operating Revenue of Parexel (by Division), FY2014-FY2017
  • Operating Revenue Structure of Parexel (by Division), FY2014-FY2017
  • Branches of Parexel in China, as of 2017H1
  • Revenue and Net Income of Charles River, 2014-2018
  • Revenue of Charles River (by Division), 2014-2018
  • Revenue Structure of Charles River (by Division), 2014-2018
  • Revenue and Net Income of Syneos, 2013-2018
  • Revenue of Syneos by Business, 2015-2018
  • Revenue Structure of Syneos by Business, 2015-2018
  • CRO Revenue and Growth of Syneos, 2015-2018
  • Revenue and Net Income of PRA, 2014-2018
  • M&A Course of ICON, 2000-2019
  • Revenue and Net Income of ICON, 2014-2018
  • Revenue of ICON by Region, 2016-2018
目次

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global contract research organization (CRO) market. Global CRO industry size sustained growth of around 8% over the years, reaching roughly $37.1 billion in 2018.

There are more than 1,100 CRO companies around the globe, led by IQVIA, Covance, LabCorp, Syneos, Charles River, Parexel, ICON, PRA, PPD and Wuxi AppTec. The world's top ten CRO players hold a combined over 50% market share for now.

China's great competitive edge over the developed countries in pharmaceutical R&D cost has allured several large international pharmaceutical companies to build dozens of R&D centers here, boosting the country's CRO industry which was worth RMB68.7 billion in 2018. The world-renowned players will continue R&D budget tilt toward CRO services and Chinese firms with more expenses on research and development will still be beneficiaries as more new drugs are approved and favorable policies are implemented. It is expected that Chinese CRO industry scale will reach a staggering RMB242.5 billion in 2025.

Large multinational and local companies play the key role in the Chinese CRO market. Thereof, global big-names or their branches in China, for instance, IQVIA, LabCorp and Parexel remain strong in research and development and capital, offering preclinical and clinical trial services.

Chinese CRO leaders include Wuxi AppTec, Pharmaron, Meidicilon, Shanghai ChemPartner, Tigermed and Joinn Laboratories. As one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs, WuXi AppTec with the strongest R&D strength not only runs the China's largest small-molecule pharmaceutical R&D service business but leads the way in global market. It seized about 10.1% of the world's CRO market in 2018.

The CRO industry in China will show three trends below:

1. CRO firms are likely to expand by way of mergers and acquisitions.

Seen from the development course of multinational CRO companies, giants expanded their business through mergers and acquisitions for better performance and greater profitability. Among them, IQVIA, Charles River, Parexel, ICON and PPD each made over 20 acquisitions over the past two decades. Also, Chinese CRO competitors follow suit to sharpen their competitiveness in recent year.

2. Favorable policies and capital promote the development of local Chinese companies.

Propelled by favorable policies and capital, Chinese CRO companies have landed in the capital market and raised funds to enhance their competitive strength.

3. The industry heads toward vertical integration

Given the importance of data cohesion between new drug R&D phases and the trustworthiness of experimental results, companies that only provide single-stage pharmaceutical R&D services cannot meet the R&D requirements of large pharmaceutical companies on the entire industry chain. Therefore, future entrants need to not only provide quality R&D and production services in their advantageous fields, but also offer comprehensive and integrated new drug research, development and production services through establishment, cooperation or M&A in the upstream and downstream of the industry chain upon customers' demand.

At present, Wuxi AppTec, taking up nearly 10% share of Chinese CRO market, is able to provide customers with integrated new drug R&D and production services as the industry's absolute leader. In the future, CRO companies will try to expand their service scope, like extending to CMO/CDMO services, and they will establish a comprehensive service platform covering the entire drug development value chain by enriching their product portfolio constantly through investment in new technologies and new facilities.

Table of Contents

1. Overview of Pharmaceutical Outsourcing

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 CRO

2. Evolution of Global CRO Industry

  • 2.1 Development History
  • 2.2 Development Background
    • 2.2.1 Pharmaceutical Industry Size
    • 2.2.2 Pharmaceutical Companies Development
    • 2.2.3 Pharmaceutical R&D
  • 2.3 Market Size
  • 2.4 Competitive Landscape

3. CRO Industry in China

  • 3.1 Development Environment
    • 3.1.1 Regulation
    • 3.1.2 Policy Environment
    • 3.1.3 Industry Environment
  • 3.2 Status Quo
  • 3.3 Market Size
  • 3.4 Competitive Landscape
  • 3.5 Development Trend
    • 3.5.1 Transnational Pharmaceutical Companies Shut Down and Have a Clearance Sale of Their Research Centers in China, which Favors Local Chinese Companies
    • 3.5.2 New Drug Approvals Increase and R&D Expenses Grow, Setting the Stage for CRO Industry
    • 3.5.3 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
    • 3.5.4 Favorable Policies and Capital Promote the Development of Local Chinese Companies
    • 3.5.5 Good Prospects Attract the Enterprises' Access into CRO Industry
    • 3.5.6 The Industry Heads toward Vertical Integration
    • 3.5.7 M&A May Become the Main Way for CRO Companies to Expand
    • 3.5.8 The Comprehensive Implementation of Consistency Assessment Brings Development Opportunities to the CRO Industry

4. Major Chinese Companies

  • 4.1 Wuxi AppTec
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 Major Clients
    • 4.1.6 R&D Investment
    • 4.1.7 CRO Business
    • 4.1.8 Development Strategy
  • 4.2 Hangzhou Tigermed
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D Investment
    • 4.2.6 Development Strategy
  • 4.3 Guangzhou Boji Pharmaceutical
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D Investment
    • 4.3.6 Development Strategy
  • 4.4 Shanghai Meidicilon Inc.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D Investment
    • 4.4.6 Major Clients
    • 4.4.7 Development Strategy
  • 4.5 Porton Fine Chemicals
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R&D Investment
    • 4.5.6 Major Clients
    • 4.5.7 Development Strategy
  • 4.6 Joinn Laboratories
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D Investment
    • 4.6.6 Major Clients
    • 4.6.7 Development Strategy
  • 4.7 Pharmaron
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D Investment
    • 4.7.6 Major Clients
    • 4.7.7 Development Strategy
  • 4.8 Obio Technology (Shanghai)
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D Investment
    • 4.8.6 Major Clients
    • 4.8.7 Development Strategy
  • 4.9 Nanjing Huawe Medicine Technology Group Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Major Clients
    • 4.9.3 Main Business
  • 4.10 Shanghai ChemPartner
    • 4.10.1 Profile
    • 4.10.2 Main Business
    • 4.10.3 Revenue Structure
    • 4.10.4 Major Clients

5 Major Foreign Companies

  • 5.1 LabCorp
    • 5.1.1 Profile
    • 5.1.2 Operation
    • 5.1.3 Revenue Structure
    • 5.1.4 CRO Business
    • 5.1.5 Development in China
  • 5.2 IQVIA
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 Revenue Structure
    • 5.2.4 Development Strategy
    • 5.2.5 Development in China
  • 5.3 Parexel
    • 5.3.1 Profile
    • 5.3.2 Operation
    • 5.3.3 Revenue Structure
    • 5.3.4 Development in China
  • 5.4 Charles River
    • 5.4.1 Profile
    • 5.4.2 Operation
    • 5.4.3 Revenue Structure
    • 5.4.4 Development in China
  • 5.5 PPD
    • 5.5.1 Profile
    • 5.5.2 Development in China
    • 5.5.3 BioDuro
    • 5.5.4 Excel PharmaStudies
  • 5.6 Syneos Health
    • 5.6.1 Profile
    • 5.6.2 Operation
    • 5.6.3 Revenue Structure
    • 5.6.4 CRO Business
    • 5.6.5 Development in China
  • 5.7 PRA
    • 5.7.1 Profile
    • 5.7.2 Operation
    • 5.7.3 Development in China
  • 5.8 ICON
    • 5.8.1 Profile
    • 5.8.2 Operation
    • 5.8.3 Revenue Structure
    • 5.8.4 Development in China
Back to Top